1 | targeted | 6,267 |
2 | oriented | 486 |
3 | imprinted | 136 |
4 | orientated | 61 |
5 | incretin-based | 60 |
6 | activity-based | 52 |
7 | molecular-targeted | 51 |
8 | nontargeted | 46 |
9 | risk-stratified | 37 |
10 | immune-based | 32 |
11 | target-based | 28 |
12 | non-study | 27 |
13 | scaled-up | 18 |
14 | well-proven | 13 |
15 | more-effective | 10 |
16 | hypertension-specific | 9 |
17 | mutation-specific | 7 |
18 | prevention-oriented | 7 |
19 | syndrome-specific | 7 |
20 | tissue-engineering | 7 |
21 | b-cell-depleting | 6 |
22 | biologically-based | 6 |
23 | cee-based | 6 |
24 | decolonizing | 6 |
25 | extinction-based | 6 |
26 | receptor-targeted | 6 |
27 | sex-linked | 6 |
28 | adoptable | 5 |
29 | b-cell-directed | 4 |
30 | embolization-based | 4 |
31 | host-directed | 4 |
32 | non-aggregating | 4 |
33 | phenotype-driven | 4 |
34 | pillared | 4 |
35 | a23187-stimulated | 3 |
36 | angiomanipulatory | 3 |
37 | management-based | 3 |
38 | mitochondria-targeting | 3 |
39 | allergen-nonspecific | 2 |
40 | anti-freeze | 2 |
41 | antimyostatin | 2 |
42 | biologic-based | 2 |
43 | glutamatergic-based | 2 |
44 | gold-free | 2 |
45 | highest-priority | 2 |
46 | hsp70-based | 2 |
47 | iv-combination | 2 |
48 | less-toxic | 2 |
49 | material-independent | 2 |
50 | muco-active | 2 |
51 | orexigen | 2 |
52 | oxygenating | 2 |
53 | radiomimetic | 2 |
54 | systemically-administered | 2 |
55 | uroantiseptic | 2 |
56 | affective-and | 1 |
57 | allergen-sit-more | 1 |
58 | alternative/novel | 1 |
59 | amyloid-centric | 1 |
60 | anti-adenovirus | 1 |
61 | anti-baff | 1 |
62 | anti-csc | 1 |
63 | antihyperglycaemia | 1 |
64 | antiproliferative-proapoptotic | 1 |
65 | antoixidant | 1 |
66 | arteaus | 1 |
67 | astrocyte-based | 1 |
68 | biotie | 1 |
69 | brca1/brca2/rad51 | 1 |
70 | cannabinoid-related | 1 |
71 | ced-based | 1 |
72 | chaperone-peptide | 1 |
73 | cocausative | 1 |
74 | cognitivo-behavioural | 1 |
75 | cytoprotective-targeted | 1 |
76 | dap12-coupled | 1 |
77 | dc-directed | 1 |
78 | double-acting | 1 |
79 | durata | 1 |
80 | effects.novel | 1 |
81 | ezetimibe-based | 1 |
82 | fgf21-based | 1 |
83 | fgfr-targeted | 1 |
84 | hae-specific | 1 |
85 | heterogeneous.in | 1 |
86 | hsp/grp-targeted | 1 |
87 | hypertension-regression | 1 |
88 | hypoxia-targeting | 1 |
89 | il-23-specific | 1 |
90 | immodulon | 1 |
91 | immunosuppressant/cytotoxic | 1 |
92 | microclosures | 1 |
93 | moab-based | 1 |
94 | ms-approved | 1 |
95 | narrow-line | 1 |
96 | neurogenerative | 1 |
97 | niacin-based | 1 |
98 | pegaptanib/sham | 1 |
99 | pegifn-based | 1 |
100 | pharmaceutical-based | 1 |
101 | program/diabetes | 1 |
102 | redox-modulating | 1 |
103 | sample-homeless | 1 |
104 | skin-rejuvenation | 1 |
105 | stimulation-based | 1 |
106 | targeted/tailored | 1 |
107 | velocity-sensitive | 1 |
1 | a23187-stimulated | 3 |
2 | activity-based | 52 |
3 | adoptable | 5 |
4 | affective-and | 1 |
5 | allergen-nonspecific | 2 |
6 | allergen-sit-more | 1 |
7 | alternative/novel | 1 |
8 | amyloid-centric | 1 |
9 | angiomanipulatory | 3 |
10 | anti-adenovirus | 1 |
11 | anti-baff | 1 |
12 | anti-csc | 1 |
13 | anti-freeze | 2 |
14 | antihyperglycaemia | 1 |
15 | antimyostatin | 2 |
16 | antiproliferative-proapoptotic | 1 |
17 | antoixidant | 1 |
18 | arteaus | 1 |
19 | astrocyte-based | 1 |
20 | b-cell-depleting | 6 |
21 | b-cell-directed | 4 |
22 | biologic-based | 2 |
23 | biologically-based | 6 |
24 | biotie | 1 |
25 | brca1/brca2/rad51 | 1 |
26 | cannabinoid-related | 1 |
27 | ced-based | 1 |
28 | cee-based | 6 |
29 | chaperone-peptide | 1 |
30 | cocausative | 1 |
31 | cognitivo-behavioural | 1 |
32 | cytoprotective-targeted | 1 |
33 | dap12-coupled | 1 |
34 | dc-directed | 1 |
35 | decolonizing | 6 |
36 | double-acting | 1 |
37 | durata | 1 |
38 | effects.novel | 1 |
39 | embolization-based | 4 |
40 | extinction-based | 6 |
41 | ezetimibe-based | 1 |
42 | fgf21-based | 1 |
43 | fgfr-targeted | 1 |
44 | glutamatergic-based | 2 |
45 | gold-free | 2 |
46 | hae-specific | 1 |
47 | heterogeneous.in | 1 |
48 | highest-priority | 2 |
49 | host-directed | 4 |
50 | hsp/grp-targeted | 1 |
51 | hsp70-based | 2 |
52 | hypertension-regression | 1 |
53 | hypertension-specific | 9 |
54 | hypoxia-targeting | 1 |
55 | il-23-specific | 1 |
56 | immodulon | 1 |
57 | immune-based | 32 |
58 | immunosuppressant/cytotoxic | 1 |
59 | imprinted | 136 |
60 | incretin-based | 60 |
61 | iv-combination | 2 |
62 | less-toxic | 2 |
63 | management-based | 3 |
64 | material-independent | 2 |
65 | microclosures | 1 |
66 | mitochondria-targeting | 3 |
67 | moab-based | 1 |
68 | molecular-targeted | 51 |
69 | more-effective | 10 |
70 | ms-approved | 1 |
71 | muco-active | 2 |
72 | mutation-specific | 7 |
73 | narrow-line | 1 |
74 | neurogenerative | 1 |
75 | niacin-based | 1 |
76 | non-aggregating | 4 |
77 | non-study | 27 |
78 | nontargeted | 46 |
79 | orexigen | 2 |
80 | orientated | 61 |
81 | oriented | 486 |
82 | oxygenating | 2 |
83 | pegaptanib/sham | 1 |
84 | pegifn-based | 1 |
85 | pharmaceutical-based | 1 |
86 | phenotype-driven | 4 |
87 | pillared | 4 |
88 | prevention-oriented | 7 |
89 | program/diabetes | 1 |
90 | radiomimetic | 2 |
91 | receptor-targeted | 6 |
92 | redox-modulating | 1 |
93 | risk-stratified | 37 |
94 | sample-homeless | 1 |
95 | scaled-up | 18 |
96 | sex-linked | 6 |
97 | skin-rejuvenation | 1 |
98 | stimulation-based | 1 |
99 | syndrome-specific | 7 |
100 | systemically-administered | 2 |
101 | target-based | 28 |
102 | targeted | 6,267 |
103 | targeted/tailored | 1 |
104 | tissue-engineering | 7 |
105 | uroantiseptic | 2 |
106 | velocity-sensitive | 1 |
107 | well-proven | 13 |
1 | brca1/brca2/rad51 | 1 |
2 | antihyperglycaemia | 1 |
3 | durata | 1 |
4 | il-23-specific | 1 |
5 | hae-specific | 1 |
6 | syndrome-specific | 7 |
7 | hypertension-specific | 9 |
8 | mutation-specific | 7 |
9 | allergen-nonspecific | 2 |
10 | amyloid-centric | 1 |
11 | radiomimetic | 2 |
12 | antiproliferative-proapoptotic | 1 |
13 | uroantiseptic | 2 |
14 | less-toxic | 2 |
15 | immunosuppressant/cytotoxic | 1 |
16 | anti-csc | 1 |
17 | risk-stratified | 37 |
18 | sex-linked | 6 |
19 | dap12-coupled | 1 |
20 | pillared | 4 |
21 | systemically-administered | 2 |
22 | targeted/tailored | 1 |
23 | hsp70-based | 2 |
24 | fgf21-based | 1 |
25 | moab-based | 1 |
26 | biologic-based | 2 |
27 | glutamatergic-based | 2 |
28 | ced-based | 1 |
29 | ezetimibe-based | 1 |
30 | cee-based | 6 |
31 | immune-based | 32 |
32 | astrocyte-based | 1 |
33 | pharmaceutical-based | 1 |
34 | pegifn-based | 1 |
35 | niacin-based | 1 |
36 | incretin-based | 60 |
37 | stimulation-based | 1 |
38 | embolization-based | 4 |
39 | extinction-based | 6 |
40 | target-based | 28 |
41 | management-based | 3 |
42 | biologically-based | 6 |
43 | activity-based | 52 |
44 | cannabinoid-related | 1 |
45 | a23187-stimulated | 3 |
46 | orientated | 61 |
47 | dc-directed | 1 |
48 | b-cell-directed | 4 |
49 | host-directed | 4 |
50 | targeted | 6,267 |
51 | cytoprotective-targeted | 1 |
52 | hsp/grp-targeted | 1 |
53 | molecular-targeted | 51 |
54 | fgfr-targeted | 1 |
55 | receptor-targeted | 6 |
56 | nontargeted | 46 |
57 | oriented | 486 |
58 | prevention-oriented | 7 |
59 | imprinted | 136 |
60 | ms-approved | 1 |
61 | affective-and | 1 |
62 | chaperone-peptide | 1 |
63 | gold-free | 2 |
64 | biotie | 1 |
65 | adoptable | 5 |
66 | narrow-line | 1 |
67 | allergen-sit-more | 1 |
68 | neurogenerative | 1 |
69 | cocausative | 1 |
70 | muco-active | 2 |
71 | more-effective | 10 |
72 | velocity-sensitive | 1 |
73 | anti-freeze | 2 |
74 | anti-baff | 1 |
75 | tissue-engineering | 7 |
76 | non-aggregating | 4 |
77 | redox-modulating | 1 |
78 | oxygenating | 2 |
79 | double-acting | 1 |
80 | mitochondria-targeting | 3 |
81 | hypoxia-targeting | 1 |
82 | b-cell-depleting | 6 |
83 | decolonizing | 6 |
84 | cognitivo-behavioural | 1 |
85 | effects.novel | 1 |
86 | alternative/novel | 1 |
87 | pegaptanib/sham | 1 |
88 | orexigen | 2 |
89 | phenotype-driven | 4 |
90 | well-proven | 13 |
91 | heterogeneous.in | 1 |
92 | antimyostatin | 2 |
93 | hypertension-regression | 1 |
94 | skin-rejuvenation | 1 |
95 | iv-combination | 2 |
96 | immodulon | 1 |
97 | scaled-up | 18 |
98 | microclosures | 1 |
99 | program/diabetes | 1 |
100 | sample-homeless | 1 |
101 | arteaus | 1 |
102 | anti-adenovirus | 1 |
103 | antoixidant | 1 |
104 | material-independent | 2 |
105 | non-study | 27 |
106 | angiomanipulatory | 3 |
107 | highest-priority | 2 |